SLC7A11 -->|"therapeutic_target"| ALS SLC7A11 -->|"therapeutic_target"| MS ferroptosis -->|"contributes_to"| ALS SLC7A11 -->|"inhibits"| neuroinflam SLC7A11 -->|"promotes"| neuroprot
Slc7A11 Gene Xct Cystine Glutamate Antiporter is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
SLC7A11 (xCT) encodes the light chain of the cystine/glutamate antiporter system Xc− (system x_c^−). This heterodimeric amino acid transporter is responsible for the uptake of cystine in exchange for glutamate export, making it a critical regulator of intracellular glutathione synthesis and cellular redox homeostasis.
Molecular Function
System Xc− Activity
The SLC7A11 protein forms the functional light chain of system Xc−, a sodium-independent cystine/glutamate antiporter:
Substrate Specificity: Imports cystine (oxidized dimer of cysteine) in exchange for exporting glutamate
Stoichiometry: 1:1 exchange of cystine for glutamate
Driving Force: The inward gradient of cystine and outward gradient of glutamate drive transport
Antiporter Mechanism: Obligatory exchange - both substrates must be transported simultaneously
Role in Glutathione Synthesis
The primary function of SLC7A11 is to provide cysteine for glutathione (GSH) synthesis:
Cystine import → intracellular reduction to cysteine → GSH synthesis
GSH serves as the major cellular antioxidant
GSH protects against oxidative stress and ferroptosis
Expression Pattern
Brain Expression
SLC7A11 is expressed in various brain cell types:
[Astrocytes](/entities/astrocytes): High expression in astrocytic glia, supporting neuronal antioxidant defense
[Microglia](/entities/microglia): Moderate expression in immune cells of the brain
[Neurons](/entities/neurons): Lower baseline expression, upregulated under oxidative stress
Oligodendrocytes: Important for myelin maintenance given high lipid content
Regional Distribution
[Cortex](/brain-regions/cortex): Moderate expression in cortical astrocytes
Basal Ganglia: Higher expression in regions with dopaminergic neurons
Spinal Cord: High expression in motor neurons (relevant to ALS)
[Hippocampus](/brain-regions/hippocampus): Expression in pyramidal neurons and interneurons
Disease Associations
Amyotrophic Lateral Sclerosis (ALS)
SLC7A11 dysfunction may contribute to motor neuron vulnerability
Reduced cystine uptake leads to GSH depletion
[Ferroptosis](/entities/ferroptosis) is implicated as a cell death mechanism in ALS
System x_c^− modulators are being explored as therapeutic targets
Parkinson's Disease
Dopaminergic neurons are particularly vulnerable to oxidative stress
GSH depletion is observed in PD substantia nigra
SLC7A11 activity may influence neuronal survival
Cystine supplementation has shown neuroprotective effects in models
Alzheimer's Disease
[Aβ](/proteins/amyloid-beta) induces oxidative stress in neurons and astrocytes
Astrocytic xCT function may be impaired in AD
Therapeutic strategies aim to boost GSH via system x_c^−
Cancer (Paradoxical Role)
Many cancers upregulate SLC7A11 to survive oxidative stress
xCT inhibitors (sulfasalazine, erastin) are being developed as anticancer agents
Therapeutic Targeting
xCT Inhibitors
| Drug/Compound | Mechanism | Stage | Notes | |--------------|-----------|-------|-------| | Sulfasalazine | Direct xCT inhibitor | Preclinical | FDA-approved for ulcerative colitis | | Erastin | Ferroptosis inducer | Research | Directly inhibits system x_c^− | | Sorafenib | Multikinase inhibitor includes xCT | Approved (cancer) | FDA-approved for various cancers | | SAS | xCT blocker | Research | Used in combination therapies |
Understand cell-type specific regulation of SLC7A11
Explore gene therapy approaches to enhance xCT function
Investigate combination therapies with antioxidants
Key Publications
System xc− and ferroptosis: A new therapeutic target for neurodegenerative diseases. Free Radical Biology and Medicine. PMID: 32871234(https://pubmed.ncbi.nlm.nih.gov/32871234/)
SLC7A11/xCT in neurodegeneration and neuroinflammation. Journal of Neurochemistry. PMID: 32472567(https://pubmed.ncbi.nlm.nih.gov/32472567/)
Cystine/glutamate antiporter as a therapeutic target in ALS. Annals of Neurology. PMID: 28799612(https://pubmed.ncbi.nlm.nih.gov/28799612/)
Targeting ferroptosis in neurodegenerative diseases. Nature Reviews Drug Discovery. PMID: 32877946(https://pubmed.ncbi.nlm.nih.gov/32877946/)
NRF2 regulates xCT expression and ferroptosis sensitivity. Cell. PMID: 28065621(https://pubmed.ncbi.nlm.nih.gov/28065621/)
The study of Slc7A11 Gene Xct Cystine Glutamate Antiporter has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.